Vaccinex starts trial of pepinemab, Bavencio combo to treat pancreatic cancer
Seeking Alpha · 03/21 16:51
BRIEF-Vaccinex Announces Initiation Of Single-Arm Open Label, Phase Ib/2 Study To Evaluate Pepinemab In Combination With Avelumab As Second Line Combination Immunotherapy For Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)
Reuters · 03/21 12:39
Vaccinex Launches Phase Ib/2 Study of Pancreatic Cancer Treatment Combination
Vaccinex Launches Phase Ib/2 Study of Pancreatic Cancer Treatment Combination
MT Newswires · 03/21 12:10
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 02/17 21:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/08 13:06
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Benzinga · 02/08 12:17
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Investor Place · 02/07 13:46
Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today?
Investor Place · 02/07 13:33
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/07 13:06
Why Is Vaccinex (VCNX) Stock Up 67% Today?
Investor Place · 02/07 12:41
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 02/07 12:23
Vaccinex Granted U.S. Patent #11572408: Treatment Of Cancer With A Semaphorin-4D Antibody In Combination With An Epigenetic Modulating Agent
Benzinga · 02/07 10:50
Vaccinex Files Prospectus Relates To Resale, From Time To Time, By Selling Stockholders Of Up To 1.6M Shares Of Common Stock
Benzinga · 01/24 18:06
Vaccinex Announces First Patient Dosed With Anti-CCR8 Antibody Licensed To Surface Oncology
Benzinga · 01/09 13:15
"Vaccinex Has Received A Notice Of Allowance For Its U.S. Patent Application 17/352,574 Titled 'Use Of Semaphorin-4D Binding Molecules For The Treatment Of Rett Syndrome'"
Benzinga · 12/07/2022 16:16
Vaccinex Announces $3.8 Million Private Placement
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that ...
GlobeNewswire · 11/28/2022 13:00
Vaccinex Closes $3.8 Million Private Placement; Shares Surge Pre-Bell
Vaccinex Closes $3.8 Million Private Placement; Shares Surge Pre-Bell
MT Newswires · 11/28/2022 09:35
Vaccinex GAAP EPS of -$0.11, revenue of $0.05M
Seekingalpha · 11/14/2022 14:14
Vaccinex Q3 EPS $(0.11) Up From $(0.17) YoY
Benzinga · 11/14/2022 13:33
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment cont...
GlobeNewswire · 11/14/2022 13:30
Webull provides a variety of real-time VCNX stock news. You can receive the latest news about Vaccinex Inc through multiple platforms. This information may help you make smarter investment decisions.
About VCNX
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). It is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington's disease (HD), and Alzheimer's disease, (AD). The Company has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.